

Figure 1



Fuc = fucosyl; Gal = galactosyl; Glc = glucosyl; GlcNAc = N-acetylglucosaminyl; Man = mannosyl; and Sia* = sialyl (NANA, N-acetylneuraminyl).

*Sia, sialic acid, which is typically NANA, 5-N-acetylneuraminic acid, (NeuAc) or NGNA, 5-N- glycolylneuraminic acid (NeuGc). Other sialic acids have been found or can be chemically synthesized.

Figure 2



Legend same as for Fig. 1

Figure 3




FLD1 A, Ex=360, Em=425 (061405\OLIGOS01.D)
LU
25
20
15
10
5
G0
G1
G2
G2S1
G2S2
15
20
25
30
35
40
45
50
55
60
m

Figure 4

A)


Bound CPM
(Labeled Ab/Anti-Id Complex)
3000
2500
2000
1500
1000
500
0.001
0.01
0.1
1
10
Competitor Ab conc. (ug/ml)
Test Ab in complex
Ab1 Gno + TNF
Ab1MAAB + TNF
Ab1PBS + TNF

B)



Bound CPM (Test Ab)
12000
10000
8000
6000
4000
2000
0
0.001
0.01
0.1
1
Anti-TNF Ab conc. (ug/ml)
Ab1 unmodified + 125I-TNF
Ab1 G2 + 125I-TNF
Ab1 G2S2(hi) + 125I-TNF
Ab2 AlaAla control + 125I-TNF

Figure 5



A
Bound CPMs (anti-Fcγlla Ab)
Competitor Ab concentration (μg/ml)
Test Ab
mAb 3G8
Ab1-Gno
Ab1-29
Ab1-20
B
Bound CPMs (anti-Fcγlla Ab)
Competitor Ab concentration (μg/ml)
Test Ab
mAb 3G8
Ab5-Gno
Ab5-26
Ab5-0
C
Bound CPMs (anti-Fcγlla Ab)
Competitor Ab concentration (μg/ml)
Test Ab
mAb 3G8
Ab1-Gno
Ab1-WGA-41
Ab1-WGA-29
D
Bound CPMs (anti-Fcγlla Ab)
Competitor Ab concentration (μg/ml)
Test Ab
mAb 3G8
Ab2-Gno
Ab2-GT-WGA-67
Ab2-GT-WGA-5

Figure 6




A
% Specific lysis
Ab1-29
Ab1-20
Ab1 Gno
Ab concentration (ng/ml)
B
% Specific lysis
Ab2-26
Ab2-0
Ab concentration (ng/ml)
C
% Specific lysis
Ab1PBS (29% sialylated)
Ab1WGAT (29% sialylated)
Ab1WGAB (32% sialylated)
Ab1WGAR (40% sialylated)
Ab1 concentration (ng/ml)
D
% Specific lysis
Ab1 unmodified (29% sialylated)
Ab1 G2S2(hi) (~95% sialylated)
Ab7 control
Ab concentration, ng/mL

Figure 7

A)


Bound CPM
4000
3000
2000
1000
0
0.001
0.01
0.1
1
10
Competitor conc. (ug/ml)
Competitor
Ab4 control
Ab1 G2 (0% sialylated)
Ab1 G2S2(hi) (~95% sialylated)

B)



Bound CPM
16000
14000
12000
10000
8000
6000
4000
2000
0
0.001
0.01
0.1
1
10
Competitor conc. (ug/ml)
Competitor
Ab4 control
Ab3(lo) (2% sialylated)
Ab3(hi) (42% sialylated)

Figure 8



AUC 10^{-3}
(day.ng/ml)
FcP1 unmodified (5% sialylated) 95 ± 1.6
FcP1 G2S2 (~98% sialylated) 48 ± 1.9
Serum conc. (ng/ml)
100000
10000
1000
100
10
0
10
20
30
40
Days after injection

Figure 9



Serum level of Ab2 (ng/ml)
100000
10000
1000
100
10
1
0
5
10
15
20
25
30
Days post-injection
Ab2 G2
Ab2 G2S2

Figure 10




A
Bound CPM
Test Ab
Ab1-29
Ab1-20
Test Ab concentration (ng/ml)
B
Bound CPM
Test Ab
Ab5-26
Ab5-0
Test Ab concentration (µg/ml)
C
Bound CPM
Test Ab
control G1 Ab
Ab1-WGA-41
Ab1-WGA-29
Test Ab concentration (ng/ml)
D
Bound CPM
Test Ab
Ab2-GT-WGA-67
Ab2-GT-WGA-5
Competitor Ab concentration (ng/ml)

Figure 11


A
Bound CPMs
8000
6000
4000
2000
0
0.001
0.01
0.1
1
10
Test Ab concentration (μg/ml)
Test Ab
Ab1-29
Ab1-20



B
Bound CPM
150000
100000
50000
0
100
1000
10000
Test Ab concentration (ng/ml)
Test Ab
control Ab
Ab2-G2-WGAB-67
Ab2-G2-WGAT-5

Figure 12




Figure 12